

 **LIVE WEBINAR**

Myeloma

an update from ASH, December 2022

Saturday, 17th December 2022 | 6.30 pm Onwards



Guest Speaker

Dr. Shaji Kumar, MD

Professor of Medicine
Mayo Clinic College of Medicine
Consultant, Division of Hematology
Medical Director
Cancer Clinical Research Office
Mayo Clinic, Rochester, USA



under the aegis of
Mumbai Hematology Group

Supported by



Guest Speaker



Dr. Shaji Kumar, MD

Dr Shaji Kumar is Consultant in the Division of Hematology & Professor of Medicine at Mayo Clinic Cancer Center in Rochester, Minnesota, US.

He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office & Vice Chair for Research in the Department of Medicine, Mayo Clinic, US.

He received MD in internal medicine from AIIMS, New Delhi. His postdoctoral training included residency in internal medicine & fellowship in hematology/oncology at the Mayo Graduate School of Medicine, Rochester, Minnesota, US.

His research focuses on development of novel drugs for treatment of myeloma.

His research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.

He also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes.

His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma.

His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.

Dr Shaji Kumar conducts NIH-funded research on translation of novel therapeutic targets in multiple myeloma as well as the role of cereblon pathways in myeloma.

He also received funding from the Multiple Myeloma Research Foundation to study the relationship between molecular profiles, treatment regimens for patients with multiple myeloma and outcomes.

Additional research, funded by the NCI, investigates the prevalence, onset and biomarkers for progression of monoclonal gammopathies.

He is on editorial advisory board, The Lancet Haematology, 2014-present; Clinical Oncology News, 2011-present; Advances in Therapy journal, 2009-present; American Journal of Hematology, 2009-2011.

He is associate editor, American Journal of Hematology, 2011-present.

He is board member, European Journal of Clinical and Medical Oncology, 2011-present; Leukemia journal, 2010-present.

He is member, Institutional Review Board, Mayo Clinic, 2009-present.

Scientific Agenda

Welcome note and introduction of guest speaker

Dr M B Agarwal, Mumbai

Guest lecture

Subject:

**Myeloma - an update from ASH,
December 2022**

Speaker

Dr. Shaji Kumar, Mayo Clinic, USA

Interactive session with Indian discussants

Moderator

Dr. M. B. Agarwal, Mumbai

Discussants

Dr. Ankit Raiyani, Ahmedabad

Dr. Asha Shah, Mumbai

Dr. Bhausahab Bagal, Mumbai

Dr. Chandrakala S, Mumba

Dr. Dharma Choudhary, Hariyana

Dr. Dipanjan Haldar, Mumbai

Dr. Hamza Dalal, Mumbai

Dr. Lingaraj Nayak, Mumbai

Dr. Muralidaran C, Mumbai

Dr. Reetu Jain, Mumbai

Dr. Shrinath Kshirsagar, Mumbai

Dr. Sreejesh Sreedharanunni, Chandigarh

Dr. Subhaprakash Sanyal, Mumbai

Dr. Yashwant Kashyap, Raipur

Vote of thanks

Dr. M. B. Agarwal, Mumbai

Faculty



Dr. Ankit Raiyani

Consultant Hematologist and BMT physician
QURE Hematology Oncology clinic
Ahmedabad



Dr Asha Shah

Consultant Hematologist
Nanavati Hospital, Holy family Hospital &
BSES Hospital
Mumbai



Dr Bhausahab Bagal

Professor & Consultant Medical oncologist
Tata Memorial Center
Mumbai



Dr Chandrakala S

Professor & Head
Dept of Clinical Hematology
KEM Hospital, Parel
Mumbai

Faculty



Dr. Dharma Choudhary, DM

Director & HOD
Blood and Marrow Transplant
Sanar International Hospital
Gurugram, Hariyana



Dr Dipanjan Haldar

Consultant Haematologist, Haemato-Oncologist &
Bone marrow transplant physician
Jupiter Hospital
Thane, Mumbai



Dr. Hamza Yusuf Dalal

Associate Consultant
Department of Hematology
Fortis Hospital
Mulund, Mumbai



Dr Lingaraj Nayak, MD, DM, DNB

Assistant Professor
Department of Medical Oncology
Tata Memorial Hospital
Mumbai

Faculty



Dr. Muralidaran C

Superspeciality Medical Officer
CTC PHO BMT Center
Borivali, Mumbai



Dr. Reetu Jain

Medical Oncologist
Jaslok Hospital and Research Center
Mumbai



Dr. Shrinath Kshirsagar

Consultant Hematologist,
Hemato-oncologist &
BMT Physician
Global Hospitals
Mumbai

Honorary Consultant
Hematologist
Dept. of Medicine
K J Somaiya Medical
College & Research Centre,
Mumbai



Dr. Sreejesh Sreedharanunni

MD, DM (Hematopathology)
Associate Professor
Dept of Hematology
Post Graduate Institute of
Medical Education & Research
Chandigarh

Faculty



Dr. Subhaprakash Sanyal

Director
Hematology and BMT services
Fortis group of hospitals
Mumbai



Dr. Yashwant Kashyap, DM (Med. Oncology)

Assistant professor
Department of Medical Oncology
All India Institute of Medical Sciences
Raipur

Registration link

Click on below link to register:

<https://forms.gle/bt5ijt7kitnJ51j8>

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.



under the aegis of
Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road,
Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

Event Partner:



Supported by

